Noninferiority trial designs for odds ratios and risk differences

Statistics in Medicine

Volumn 29, Issue 9, 2010, Pages 982-993

  Hilton, Joan F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active controlled trial; Allocation ratio; Ancillary parameter

Indexed keywords

ARTICLE; ATTRIBUTABLE RISK; CLINICAL STUDY; METHODOLOGY; NONINFERIORITY TRIAL DESIGN; PARAMETER; RISK; SAMPLE SIZE; STATISTICAL MODEL;

ALGORITHMS; BIOSTATISTICS; HEPATITIS C; HUMANS; LIKELIHOOD FUNCTIONS; MODELS, STATISTICAL; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77950868646     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3846     Document Type: Article

References (45)

1. Dibra A, Kastrati A, Mehilli J, Pache J, Schhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schmig A. ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. New England Journal of Medicine 2005; 353:663-670. DOI: 10.1056/NEJMoa044372. (Pubitemid 41175674)
2. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pirart M, Mauer ME, Collette L. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine 2009; 360:2516-2527. DOI: 10.1056/NEJMoa0810095.
3. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. New England Journal of Medicine 2009; 360:2055-2065. DOI: 10.1056/NEJMoa0810266.
4. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, DahlŽf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW. PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New England Journal of Medicine 2008; 359:1238-1251. DOI: 10.1056/NEJMoa0805002.
5. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine 2008; 358:36-46. DOI: 10.1056/NEJMoa073149.
6. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ. RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. New England Journal of Medicine 2007; 357:28-38. DOI: 10.1056/NEJMoa073394. (Pubitemid 47026732)
7. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. New England Journal of Medicine 2006; 354:1464-1476. DOI: 10.1056/NEJMoa055443.
8. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, KrŽning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Sch§ller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. New England Journal of Medicine 2005; 352:2696-2704. DOI: 10.1056/NEJMoa043116. (Pubitemid 41007824)
9. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. New England Journal of Medicine 2004; 350:2050-2059. DOI: 10.1056/NEJMoa032651.
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004; 350:1495-1504. Erratum in: New England Journal of Medicine 2006; 354: 778. DOI: 10.1056/NEJMoa040583.
11. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003; 349:1893-1906. Erratum in: New England Journal of Medicine 2004; 350: 203. DOI: 10.1056/NEJMoa032292.
12. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mckel M, Ochala A, Kellock A, Parise H, Mehran R. HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine 2009; 360:1946-1959. DOI: 10.1056/NEJMoa0810116.
13. van Gogh Investigators, Büller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine 2007; 357:1094-1104. DOI: 10.1056/NEJMoa064247. (Pubitemid 47443214)
14. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L. TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. New England Journal of Medicine 2001; 344:1888-1894.
15. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sol R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine 2007; 357:124-134. DOI: 10.1056/NEJMoa066403.
16. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. New England Journal of Medicine 2007; 357:1685-1694. DOI: 10.1056/NEJMoa070546.
17. Mas JL, Chatellier G, Beyssen B, Branchereau A, Moulin T, Becquemin JP, Larrue V, Livre M, Leys D, Bonneville JF, Watelet J, Pruvo JP, Albucher JF, Viguier A, Piquet P, Garnier P, Viader F, Touz E, Giroud M, Hosseini H, Pillet JC, Favrole P, Neau JP, Ducrocq X. EVA-3S Investigators. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. New England Journal of Medicine 2006; 355:1660-1671. DOI: 10.1056/NEJMoa061752.
18. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. New England Journal of Medicine 2007; 356:2472-2482. DOI: 10.1056/NEJMoa066906.
19. Fowler Jr VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Ftkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New England Journal of Medicine 2006; 355:653-665. DOI: 10.1056/NEJMoa053783.
20. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, Lockshin M, Merrill JT, Belmont HM, Askanase AD, McCune WJ, Hearth-Holmes M, Dooley MA, Von Feldt J, Friedman A, Tan M, Davis J, Cronin M, Diamond B, Mackay M, Sigler L, Fillius M, Rupel A, Licciardi F, Buyon JP. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. New England Journal of Medicine 2005; 353:2550-2558. DOI: 10.1056/NEJMoa051135.
21. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. New England Journal of Medicine 2002; 347:1834-1840. DOI: 10.1056/NEJMoa021375.
22. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK. Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine 2006; 354:251-260. DOI: 10.1056/NEJMoa051871.
23. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New England Journal of Medicine 2005; 353:2219-2228. DOI: 10.1056/NEJMoa043731.
24. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B. Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. New England Journal of Medicine 2005; 353:770-781. DOI: 10.1056/NEJMoa050085.
25. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New England Journal of Medicine 2004; 351:1391-1402. DOI: 10.1056/NEJMoa040446.
26. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C, Omari S, Urassa A, Mshinda H, Jumanne A, Salim N, Shomari M, Aebi T, Schellenberg DM, Carter T, Villafana T, Demoiti MA, Dubois MC, Leach A, Lievens M, Vekemans J, Cohen J, Ballou WR, Tanner M. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. New England Journal of Medicine 2008; 359:2533-2544. DOI: 10.1056/NEJMoa0807773.
27. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. New England Journal of Medicine 2007; 356:2571-2581. DOI: 10.1056/NEJMoa066536.
28. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Sthle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New England Journal of Medicine 2009; 360:961-972. DOI: 10.1056/NEJMoa0804626.
29. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. New England Journal of Medicine 2007; 357:2576-2588. DOI: 10.1056/NEJMoa066422. (Pubitemid 350294224)
30. Lacroix J, Hbert PC, Hutchison JS, Hume HA, Tucci M, Ducruet T, Gauvin F, Collet JP, Toledano BJ, Robillard P, Joffe A, Biarent D, Meert K, Peters MJ. TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network. Transfusion strategies for patients in pediatric intensive care units. New England Journal of Medicine 2007; 356:1609-1619. DOI: 10.1056/NEJMoa066240. (Pubitemid 46631670)
31. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K. Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. New England Journal of Medicine 2004; 351:1493-1501. DOI: 10.1056/NEJMoa040127.
32. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine 2003; 349:1695-1702. Erratum in: New England Journal of Medicine 2004; 350:423. DOI: 10.1056/NEJMoa035451. (Pubitemid 37315006)
33. De Boo TM, Zielhuis GA. Minimization of sample size when comparing two small probabilities in a non-inferiority safety trial. Statistics in Medicine 2004; 23:1683-1699. DOI: 10.1002/sim.1760. (Pubitemid 38765339)
34. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Statistics in Medicine 1990; 9:1447-1454.
35. Jewell NP. Statistics for Epidemiology. Chapman & Hall/CRC: Boca Raton, 2004; 77-78.
36. Miettinen O, Nurminen M. Comparative analysis of two rates. Statistics in Medicine 1985; 4:213-226.
37. Chow SC, Shao J, Wang H (eds). Sample Size Calculations in Clinical Research. Marcel Dekker: New York, 2003.
38. Pocock SJ. The pros and cons of noninferiority trials. Fundamental and Clinical Pharmacology 2003; 17:483-490.
39. Roebruck P, Kühn A. Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilities. Statistics in Medicine 1995; 14:1583-1594.
40. Fleiss JL. Statistical Methods for Rates and Proportions. Wiley: New York, 1981.
41. Hilton JF. Designs of superiority and noninferiority trials for binary responses are noninterchangeable. Biometrical Journal 2006; 48:934-947. DOI: 10.1002/bimj.200510288.
42. Chan ISF. Power and sample size determination for noninferiority trials using an exact method. Journal of Biopharmaceutical Statistics 2002; 12:457-469. (Pubitemid 35439794)
43. D'Agostino Sr RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22:169-186.
44. Hung HM, Wang SJ, O'Neill R. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical Journal 2005; 47:28-36. (Pubitemid 40390436)
45. Chow SC, Shao J. On non-inferiority margin and statistical tests in active control trials. Statistics in Medicine 2006; 25:1101-1113.